ClinicalTrials.gg
CompletedNCT01512758Updated Mar 15, 2019Results posted

A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or Lymphomas

A Phase 1 interventional study of Alisertib in Advanced Solid Tumors and Lymphomas, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 1 site in Singapore. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-15.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 26 studies in Lymphoma by Takeda — 1 open to participants now, 2 under way, none of them phase 3. Lymphoma · Takeda.

Enrollment
12th of 23
36 · median 36
Started
2012
with 2 others
Phase 1
12 of 26
none open now
Registered
8th of 26
by date

Among the 26 studies in Lymphoma by Takeda, this one is the 12th largest by enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2012, is one of 12 in phase 1, and was the 8th registered.

Lymphoma

3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.

Browse Lymphoma studies →

Open to participants now

1 of the 26 studies in Lymphoma by Takeda is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Lymphoma by Takeda, or all of them as a file.
02

Study summary

The purpose of this study was to determine the safety profile, maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and to characterize the pharmacokinetic (PK) profile of alisertib twice daily (BID) dosing for 7 days in East Asian participants with advanced solid tumors or lymphomas. The secondary objective was to describe any antitumor activity that may have been observed with alisertib treatment.

Read the detailed description

The drug being tested in this study is called alisertib (MLN8237). Alisertib is being tested to treat people who have advanced solid tumors or lymphomas for which standard curative or life-prolonging treatment did not exist or was no longer effective or tolerable. This study evaluated the safety and pharmacokinetic (PK) profile, and maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of alisertib, as well as any antitumor activity.

The study enrolled 36 patients. Participants were assigned to one of the two treatment groups and received:

  • Alisertib 30 mg
  • Alisertib 40 mg All participants took two enteric-coated tablets every 12 hours each day for 7 days followed by a 14-day rest period in a 21-day cycle for up to 16 cycles.

This multi-center trial is conducted in East Asia. The overall time to participate in this study was 24 months, unless it was determined that a participant would derive benefit from continued therapy beyond 24 months. Participants made multiple visits to the clinic, and were contacted up to a maximum of 30 days after last dose of study drug for a follow-up assessment.

03

Conditions studied

  • Advanced Solid Tumors
  • Lymphomas

Browse trials for

Keywords

  • East Asian Patients
  • Advanced solid tumors
  • Lymphomas
  • MLN8237
  • Alisertib
  • Aurora A Kinase Inhibitor
  • Drug therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female East Asian participants 18 years or older
  • or cytologically confirmed and/or advanced solid tumors or lymphomas for which no effective standard treatment is available
  • (ECOG) performance status 0 or 1
  • Expected survival longer than 3 months from study enrollment
  • Radiographically or clinically evaluable tumor
  • Female participants who are post menopausal for at least 1 year, surgically sterile, or agree to practice 2 effective methods of through 30 days after the last dose of study drug or agree to abstain from heterosexual intercourse
  • Male participants who agree to practice effective barrier contraception through 6 months after the last dose of alisertib or agree to abstain from heterosexual intercourse
  • Voluntary written consent

Exclusion criteria

Exclusion Criteria:

  • Female participants who are lactating or pregnant
  • Treatment with any products, systemic antineoplastic treatment, or antineoplastic treatment with within 21 days preceding the first dose of alisertib
  • Treatment with nitrosoureas, mitomycin C, rituximab, alemtuzumab, or other unconjugated antibody treatment within 42 days (21 days if clear evidence of progressive disease)
  • Medical conditions requiring daily, chronic, or regular use of proton pump inhibitors or H2-receptor antagonists
  • Treatment with radioimmunoconjugates such as ibritumomab tiuxetan or tositumomab within 56 days preceding first alisertib dose
  • Major surgery within the 14 days preceding the first dose of alisertib
  • Life-threatening or uncontrolled medical illness unrelated to cancer
  • Known gastrointestinal (GI) disease or procedures that could interfere with the oral absorption or tolerance of alisertib
  • Inability to swallow capsules
  • Inadequate bone marrow or other organ function
  • Diagnosed or treated for another within 2 years of first dose of alisertib, or previously diagnosed with another malignancy and have any radiographic or biochemical marker evidence of active disease. In the case of prior prostate cancer treated with radiotherapy, the prostate specific antigen (PSA) may be detectable, but must be \< 1 ng/mL. Participants with completely resected basal cell carcinoma, squamous cell carcinoma of the skin, or in situ malignancy of any type are not excluded
  • Other severe acute or chronic medical or psychiatric conditions, including uncontrolled diabetes, or laboratory abnormality
  • Known or suspected (HIV) positive or surface antigen-positive status, or known or suspected active infection
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Alisertib 30 mg

    Alisertib 30 mg enteric-coated tablets (ECT), orally, twice a day (BID) for 7 days, followed by a 14-day rest period, in 21-day cycles until there is evidence of disease progression or unacceptable alisertib-related toxicities (up to 16 cycles). Cycles could be extended to 28-day cycles (with additional 7-day rest period) if all alisertib-related toxicities (except alopecia) were not resolved to less than Grade 2.

    Drug: Alisertib

  • Experimental
    Alisertib 40 mg

    Alisertib 40 mg ECT, orally, BID for 7 days, followed by a 14-day rest period, in 21-day cycles until there is evidence of disease progression or unacceptable alisertib-related toxicities (up to 7 cycles). Cycles could be extended to 28-day cycles (with additional 7-day rest period) if all alisertib-related toxicities (except alopecia) were not resolved to less than Grade 2.

    Drug: Alisertib

Interventions

  • Alisertib enteric-coated tablets

    Also known as: MLN8237

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)

    MTD was defined as highest dose at which \<2 participants experienced a dose-limiting toxicity (DLT). DLT was defined as any of the following events considered possibly related to therapy with alisertib by the investigator: 1. Grade 4 neutropenia (absolute neutrophil count \<500 cells/mm\^3) for \>7 days; 2. Grade 4 neutropenia with fever (oral or ear temperature ≥38.5°C); 3. Grade 4 thrombocytopenia (platelets \<25,000/mm\^3) for \>7 days; 4. Platelet count \<10,000 cells/mm\^3; 5. ≥Grade 3 thrombocytopenia with clinically significant bleeding; 6. Delay in initiation of subsequent cycle by \>7 days due to treatment-related toxicity; 7. ≥Grade 3 nonhematological toxicity except following: a. ≥Grade 3 nausea and/or emesis in the absence of optimal antiemetic therapy; b. ≥Grade 3 diarrhea in the absence of optimal supportive therapy; c. Grade 3 fatigue lasting \<1 week; d. Other Grade 3 nonhematological toxicity that can be safely and reliably controlled to ≤Grade 2 with appropriate treatment.

    Time frame: Treatment Cycle 1

  2. Number of Participants With Adverse Events and Serious Adverse Events

    An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A Serious Adverse Event (SAE) A serious is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.

    Time frame: First dose to 30 days past last dose (Up to 12.1 Months)

  3. Number of Participants With Abnormal Clinical Laboratory Values Reported as Adverse Events

    Laboratory AEs in the following system organ classes (SOCs) are reported: blood and lymphatic system disorders, investigations, and metabolism and nutrition disorders. An abnormal laboratory value was assessed as an AE if that value lead to discontinuation or delay in treatment, dose modification, therapeutic intervention, or was considered by the investigator to be a clinically significant change from baseline. A treatment¬-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.

    Time frame: First dose to 30 days past last dose (Up to 12.1 Months)

  4. Number of Participants With Clinically Significant Changes in Vital Signs Reported as Adverse Events

    Vital signs (blood pressure, pulse rate, and oral temperature) measurements were collected throughout the study.

    Time frame: First dose to 30 days past last dose (Up to 12.1 Months)

  5. Cmax: Maximum Observed Concentration for Alisertib

    Time frame: Cycle 1 Days 1 and 7 predose and at multiple time points (up to 12 hours) postdose

  6. Tmax: Time to First Occurrence of Cmax for Alisertib

    Time frame: Cycle 1 Days 1 and 7 predose and at multiple time points (up to 12 hours) postdose

  7. AUCτ: Area Under the Concentration-Time Curve From Time 0 to End of Dosing Interval (τ) for Alisertib

    Time frame: Cycle 1 Days 1 and 7 predose and at multiple time points (up to 12 hours) postdose

  8. Dose Normalized AUCτ: Area Under the Concentration-Time Curve From Time 0 to Time t for Alisertib

    Dose normalized AUCτ was obtained using AUCτ divided by alisertib dose in milligrams.

    Time frame: Cycle 1 Day 7 predose and at multiple time points (up to 12 hours) postdose

  9. T1/2: Terminal Half-Life for Alisertib

    Time frame: Cycle 1 Day 7 predose and at multiple time points (up to 12 hours) postdose

  10. Rac: Accumulation Ratio for Alisertib

    Time frame: Cycle 1 Day 7 predose and at multiple time points (up to 12 hours) postdose

  11. PTR: Peak Trough Ratio During a Dosing Interval, at Steady State for Alisertib

    Time frame: Cycle 1 Day 7 predose and at multiple time points (up to 12 hours) postdose

  12. CLss/F: Apparent Clearance After Extravascular Administration, at Steady State, Calculated Using AUCτ for Alisertib

    Time frame: Cycle 1 Day 7 predose and at multiple time points (up to 12 hours) postdose

Secondary outcomes

  1. Best Overall Response Rate Based on Investigator Assessment

    Best overall response rate is defined as the percentage of participants with complete response (CR) and/or partial response (PR) as assessed by the Investigator using Lymphoma International Working Group (IWG) Criteria or Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1 for target lesions and assessed by CT, PET or MRI. IWG criteria for CR is defined as the disappearance of all evidence of disease and PR is defined as regression of measurable disease and no new sites. RECIST response criteria is defined as: CR is defined as disappearance of all target lesions and PR is defined as 30% decrease in the sum of the longest diameter of target lesions.

    Time frame: Baseline and every 2 cycles for up to 24 months or until progressive disease

  2. Duration of Response

    DOR is defined as the time from the date of first documentation of a CR response to the date of first documentation of PD according to IWG criteria or RECIST criteria 1.1. IWG PD is defined as PD is defined as any new lesion or increase by \>50% of previously involved sites from nadir. RECIST PD is defined as unequivocal progression of existing non-target lesions.

    Time frame: First documented response until disease progression; approximately 12 months

  3. Concentrations of Relevant Tumor Markers

    Time frame: Cycle 1, Day 1; at end of Cycle 2 and every 2 cycles thereafter; and at end treatment; approximately 12 months

07

Results

Posted Mar 15, 2019

Participant flow

Participants took part in the study at 8 investigative sites in Singapore, Taiwan, Hong Kong, and South Korea from 06 February 2012 to 08 October 2013.

Participant flow — Overall Study
MilestoneAlisertib 30 mgAlisertib 40 mg
Started306
Completed306
Not completed00

Outcome measures

PrimaryMaximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)

MTD was defined as highest dose at which \<2 participants experienced a dose-limiting toxicity (DLT). DLT was defined as any of the following events considered possibly related to therapy with alisertib by the investigator: 1. Grade 4 neutropenia (absolute neutrophil count \<500 cells/mm\^3) for \>7 days; 2. Grade 4 neutropenia with fever (oral or ear temperature ≥38.5°C); 3. Grade 4 thrombocytopenia (platelets \<25,000/mm\^3) for \>7 days; 4. Platelet count \<10,000 cells/mm\^3; 5. ≥Grade 3 thrombocytopenia with clinically significant bleeding; 6. Delay in initiation of subsequent cycle by \>7 days due to treatment-related toxicity; 7. ≥Grade 3 nonhematological toxicity except following: a. ≥Grade 3 nausea and/or emesis in the absence of optimal antiemetic therapy; b. ≥Grade 3 diarrhea in the absence of optimal supportive therapy; c. Grade 3 fatigue lasting \<1 week; d. Other Grade 3 nonhematological toxicity that can be safely and reliably controlled to ≤Grade 2 with appropriate treatment.

Time frame:
Treatment Cycle 1
Reported as:
Number · mg
Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)
mgAlisertib 30 mg or 40 mg
Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)30
PrimaryNumber of Participants With Adverse Events and Serious Adverse Events

An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A Serious Adverse Event (SAE) A serious is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.

Time frame:
First dose to 30 days past last dose (Up to 12.1 Months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events and Serious Adverse Events
ParticipantsAlisertib 30 mgAlisertib 40 mg
AE306
SAE154
PrimaryNumber of Participants With Abnormal Clinical Laboratory Values Reported as Adverse Events

Laboratory AEs in the following system organ classes (SOCs) are reported: blood and lymphatic system disorders, investigations, and metabolism and nutrition disorders. An abnormal laboratory value was assessed as an AE if that value lead to discontinuation or delay in treatment, dose modification, therapeutic intervention, or was considered by the investigator to be a clinically significant change from baseline. A treatment¬-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.

Time frame:
First dose to 30 days past last dose (Up to 12.1 Months)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Clinical Laboratory Values Reported as Adverse Events
ParticipantsAlisertib 30 mgAlisertib 40 mg
Neutropenia195
Anaemia94
Thrombocytopenia61
Febrile neutropenia41
Leukopenia22
White blood cell count decreased70
Aspartate aminotransferase increased60
Neutrophil count decreased40
Alanine aminotransferase increased40
Platelet count decreased30
Blood bilirubin increased20
Haemoglobin decreased10
Blood creatinine increased01
Urine output decreased10
Hypokalaemia43
Hypercalcaemia01
Hyponatraemia10
PrimaryNumber of Participants With Clinically Significant Changes in Vital Signs Reported as Adverse Events

Vital signs (blood pressure, pulse rate, and oral temperature) measurements were collected throughout the study.

Time frame:
First dose to 30 days past last dose (Up to 12.1 Months)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Vital Signs Reported as Adverse Events
ParticipantsAlisertib 30 mgAlisertib 40 mg
Hypertension10
Hypotension10
Bradycardia10
Pyrexia81
PrimaryCmax: Maximum Observed Concentration for Alisertib
Time frame:
Cycle 1 Days 1 and 7 predose and at multiple time points (up to 12 hours) postdose
Reported as:
Mean · nM
Cmax: Maximum Observed Concentration for Alisertib
nMAlisertib 30 mgAlisertib 40 mg
Day 11442.5 ± 534.801871.7 ± 429.62
Day 73000.0 ± 1329.383686.7 ± 885.45
PrimaryTmax: Time to First Occurrence of Cmax for Alisertib
Time frame:
Cycle 1 Days 1 and 7 predose and at multiple time points (up to 12 hours) postdose
Reported as:
Median · hr
Tmax: Time to First Occurrence of Cmax for Alisertib
hrAlisertib 30 mgAlisertib 40 mg
Day 13.0 (2 to 8)2.0 (2 to 3)
Day 72.9 (1 to 6)2.0 (1 to 3)
PrimaryAUCτ: Area Under the Concentration-Time Curve From Time 0 to End of Dosing Interval (τ) for Alisertib
Time frame:
Cycle 1 Days 1 and 7 predose and at multiple time points (up to 12 hours) postdose
Reported as:
Mean · nM*hr
AUCτ: Area Under the Concentration-Time Curve From Time 0 to End of Dosing Interval (τ) for Alisertib
nM*hrAlisertib 30 mgAlisertib 40 mg
Day 19549.0 ± 4119.3011811.7 ± 2845.76
Day 724377.9 ± 13261.6130683.3 ± 9575.68
PrimaryDose Normalized AUCτ: Area Under the Concentration-Time Curve From Time 0 to Time t for Alisertib

Dose normalized AUCτ was obtained using AUCτ divided by alisertib dose in milligrams.

Time frame:
Cycle 1 Day 7 predose and at multiple time points (up to 12 hours) postdose
Reported as:
Mean · nM*hr/mg
Dose Normalized AUCτ: Area Under the Concentration-Time Curve From Time 0 to Time t for Alisertib
nM*hr/mgAlisertib 30 mgAlisertib 40 mg
Dose Normalized AUCτ: Area Under the Concentration-Time Curve From Time 0 to Time t for Alisertib812.9 ± 441.90766.8 ± 238.88
PrimaryT1/2: Terminal Half-Life for Alisertib
Time frame:
Cycle 1 Day 7 predose and at multiple time points (up to 12 hours) postdose
Reported as:
Mean · hr
T1/2: Terminal Half-Life for Alisertib
hrAlisertib 30 mgAlisertib 40 mg
T1/2: Terminal Half-Life for Alisertib16.750 ± 8.171014.795 ± 4.5715
PrimaryRac: Accumulation Ratio for Alisertib
Time frame:
Cycle 1 Day 7 predose and at multiple time points (up to 12 hours) postdose
Reported as:
Mean · ratio
Rac: Accumulation Ratio for Alisertib
ratioAlisertib 30 mgAlisertib 40 mg
Rac: Accumulation Ratio for Alisertib2.830 ± 1.29552.690 ± 1.0638
PrimaryPTR: Peak Trough Ratio During a Dosing Interval, at Steady State for Alisertib
Time frame:
Cycle 1 Day 7 predose and at multiple time points (up to 12 hours) postdose
Reported as:
Mean · ratio
PTR: Peak Trough Ratio During a Dosing Interval, at Steady State for Alisertib
ratioAlisertib 30 mgAlisertib 40 mg
PTR: Peak Trough Ratio During a Dosing Interval, at Steady State for Alisertib2.254 ± 0.64582.207 ± 0.3946
PrimaryCLss/F: Apparent Clearance After Extravascular Administration, at Steady State, Calculated Using AUCτ for Alisertib
Time frame:
Cycle 1 Day 7 predose and at multiple time points (up to 12 hours) postdose
Reported as:
Mean · L/hr
CLss/F: Apparent Clearance After Extravascular Administration, at Steady State, Calculated Using AUCτ for Alisertib
L/hrAlisertib 30 mgAlisertib 40 mg
CLss/F: Apparent Clearance After Extravascular Administration, at Steady State, Calculated Using AUCτ for Alisertib2.9357 ± 1.370912.8083 ± 1.20259
SecondaryBest Overall Response Rate Based on Investigator Assessment

Best overall response rate is defined as the percentage of participants with complete response (CR) and/or partial response (PR) as assessed by the Investigator using Lymphoma International Working Group (IWG) Criteria or Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1 for target lesions and assessed by CT, PET or MRI. IWG criteria for CR is defined as the disappearance of all evidence of disease and PR is defined as regression of measurable disease and no new sites. RECIST response criteria is defined as: CR is defined as disappearance of all target lesions and PR is defined as 30% decrease in the sum of the longest diameter of target lesions.

Time frame:
Baseline and every 2 cycles for up to 24 months or until progressive disease
Reported as:
Number · percentage of participants
Best Overall Response Rate Based on Investigator Assessment
percentage of participantsAlisertib 30 mgAlisertib 40 mg
CR00
PR30
SecondaryDuration of Response

DOR is defined as the time from the date of first documentation of a CR response to the date of first documentation of PD according to IWG criteria or RECIST criteria 1.1. IWG PD is defined as PD is defined as any new lesion or increase by \>50% of previously involved sites from nadir. RECIST PD is defined as unequivocal progression of existing non-target lesions.

Time frame:
First documented response until disease progression; approximately 12 months
Reported as:
Median · days
Duration of Response
daysAlisertib 30 mgAlisertib 40 mg
Duration of Response169 (169 to 169)—
SecondaryConcentrations of Relevant Tumor Markers
Time frame:
Cycle 1, Day 1; at end of Cycle 2 and every 2 cycles thereafter; and at end treatment; approximately 12 months

No measurements were reported for this outcome.

Adverse events

Collected over First dose to 30 days past last dose (Up to 12.1 Months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Alisertib 30 mg—15/30 (50%)30/30 (100%)
Alisertib 40 mg—4/6 (66.7%)6/6 (100%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventAlisertib 30 mgAlisertib 40 mg
NeutropeniaBlood and lymphatic system disorders2/303/6
Febrile neutropeniaBlood and lymphatic system disorders4/301/6
AnaemiaBlood and lymphatic system disorders1/301/6
LeukopeniaBlood and lymphatic system disorders1/301/6
StomatitisGastrointestinal disorders3/301/6
Subcutaneous abscessInfections and infestations0/301/6
Cancer painNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/301/6
HypokalaemiaMetabolism and nutrition disorders0/301/6
DiarrhoeaGastrointestinal disorders2/300/6
Upper gastrointestinal haemorrhageGastrointestinal disorders1/300/6
Most frequent other events
Showing 10 of 56
Most frequent other events
EventAlisertib 30 mgAlisertib 40 mg
NeutropeniaBlood and lymphatic system disorders19/303/6
DiarrhoeaGastrointestinal disorders17/303/6
StomatitisGastrointestinal disorders16/302/6
AnaemiaBlood and lymphatic system disorders8/303/6
AlopeciaSkin and subcutaneous tissue disorders14/303/6
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders3/303/6
Rash maculo-papularSkin and subcutaneous tissue disorders3/303/6
HypokalaemiaMetabolism and nutrition disorders4/303/6
LethargyNervous system disorders0/303/6
FatigueGeneral disorders12/302/6

Baseline characteristics

Safety Population is defined as all participants who received at least one dose of alisertib.

Age, Continuous
Age, Continuous(years)Alisertib 30 mgAlisertib 40 mgTotal
Mean57.2 ± 9.5250.7 ± 18.2556.1 ± 11.35
Sex: Female, Male
Sex: Female, Male(Participants)Alisertib 30 mgAlisertib 40 mgTotal
Female11213
Male19423
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Alisertib 30 mgAlisertib 40 mgTotal
Asian (Chinese)17522
Asian (Korean)13013
Malay011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Alisertib 30 mgAlisertib 40 mgTotal
Not Hispanic or Latino30636
Region of Enrollment
Region of Enrollment(Participants)Alisertib 30 mgAlisertib 40 mgTotal
Singapore4610
Taiwan808
Hong Kong505
Korea, Republic of13013
Height
Height(cm)Alisertib 30 mgAlisertib 40 mgTotal
Mean162.5 ± 6.84161.9 ± 6.61162.4 ± 6.71
Weight
Weight(kg)Alisertib 30 mgAlisertib 40 mgTotal
Mean57.78 ± 9.25562.30 ± 11.71458.53 ± 9.669
Body Surface Area (BSA)
Body Surface Area (BSA)(m^2)Alisertib 30 mgAlisertib 40 mgTotal
Mean1.611 ± 0.14871.667 ± 0.16131.620 ± 0.1499
08

Study locations

1 site
  • National Cancer Centre
    Tiong Bahru, 169610, Singapore
09

References and documents

Publications

  • Venkatakrishnan K, Kim TM, Lin CC, Thye LS, Chng WJ, Ma B, Chen MH, Zhou X, Liu H, Kelly V, Kim WS. Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose. Invest New Drugs. 2015 Aug;33(4):942-53. doi: 10.1007/s10637-015-0258-y. Epub 2015 Jun 19. PubMed 26084989 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2012 to primary completion in Oct 2013, 20 months.

Results were first posted in Mar 2019, 5 years 5 months after primary completion.

Of 143 industry-sponsored phase 1 interventional studies under Lymphoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 61. This study's 20 months is below that.

Counting every sponsor, half of 281 studies reached it within 53 months; a quarter within 34 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2012
First posted
Jan 19, 2012
StartActual
Feb 6, 2012
Primary completionActual
Oct 8, 2013
CompletionActual
Oct 8, 2013
Results first posted
Mar 15, 2019
Last update
Mar 15, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01512758
Responsible party
Sponsor
First posted
Jan 19, 2012
Start date
Feb 6, 2012
Primary completion
Oct 8, 2013
Completion
Oct 8, 2013
Results posted
Mar 15, 2019
Last update
Mar 15, 2019

Study contacts

Medical Director Clinical Science
study director · Millennium Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MLN 8237

Start the discussion